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The recentlymodiﬁed CHROMagar Acinetobactermediumwas evaluated for detection of carbapenemase-producing
Acinetobacter baumannii from spiked stools. A total of 45 Acinetobacter spp. isolates were tested. The CHROMagar
Acinetobactermediumhad a high sensitivity of 86.5% and a speciﬁcity of 75%. Thismedium is likely to bemost useful
for controlling outbreaks and in endemic situations.
Acinetobacter spp. are an important source of healthcare-associated
infections. The spread of carbapenemase-producing Acinetobacter spp.
is increasingly reported worldwide associated with multidrug resis-
tance (Bonnin et al., 2013a; Poirel and Nordmann, 2006; Wareham
et al., 2008). Therefore, targeted surveillance of high-risk patients
based on screening of carriers is essential to control the spread of
carbapenem-resistant Acinetobacter spp. (CRAB). Resistance to carba-
penems in Acinetobacter spp. may result from decreased permeability
of the outermembrane,modiﬁcation of penicillin-bindingproteins, pro-
duction of carbapenemases, and mostly from combined resistance
mechanisms (Bonnin et al., 2013a; Poirel and Nordmann, 2006;
Fernández-Cuenca et al., 2003). Carbapenemases in Acinetobacter spp.
belong to Ambler class A (KPC and some GES variants) (Bonnin et al.,
2013b; Robledo et al., 2010), class B (VIM, IMP, SIM, NDM) (Bonnin
et al., 2012; Poirel and Nordmann, 2006), and mostly class D
(oxacillinases) (Bonnin et al., 2013a). Five main groups of oxacillinases
with carbapenemase activity have been identiﬁed in A. baumannii,
i.e., the intrinsic chromosomal OXA-51-like and the acquired chromo-
somally and plasmid-encoded OXA-23-like, OXA-40-like, OXA-58-like,
and OXA-143-like enzymes (Bonnin et al., 2013a; Higgins et al., 2009;
Poirel and Nordmann, 2006). When the blaOXA-51-like genes are
expressed at a basal level, they do not confer carbapenem resistance.
However, the insertion of the insertion sequence ISAba1 upstream of
the blaOXA-51-like gene may lead to overexpression of this oxacillinase
gene leading to carbapenem resistance (Turton et al., 2006). Selective
media developed for detection of carbapenem-resistant Enterobacteria-
ceae are inappropriate for detection of CRAB, since Acinetobacter spp.
are intrinsically resistant to several carbapenem molecules that
are contained in those selective media. CHROMagar Acinetobacter
(CHROMagar, Paris, France) is a selective medium designed for rapid
identiﬁcation of CRAB inhibiting the growth of yeast, carbapenem-
susceptible Gram negatives and Gram positives, and coloring the colo-
nies of Acinetobacter spp. in red since it contains a chromogenic mole-
cule (Ajao et al., 2011; Gordon and Wareham, 2009). A new formula
of thismediumhas been recently developed (Song et al., 2013). As com-
pared to the previous version of the CHROMagar Acinetobactermedium,
it contains an antimicrobial selective supplement (CR102; CHROMagar)
aimed to select for CRAB.
While previous studies on previous formulas of this medium
included strains for which the molecular mechanisms of resistance
was not determined, our aim was to evaluate the performance of this
CHROMagar Acinetobacter medium using a set of precisely molecular-
deﬁned carbapenemase producers. Spiked stools were used to mimic
the in vivo colonization of stools.
Forty-ﬁve Acinetobacter spp. isolates (mostly A. baumannii) were
tested, including 37 acquired carbapenemase producers as follows:
Ambler class A (GES-11-, GES-14-type) producers (n = 2), Ambler
class B (IMP, VIM, SIM, NDM-type) producers (n = 7), Ambler class D
(OXA-23-type, OXA-40-type, OXA-58-type) producers (n = 28), and 8
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strains that do not produce acquired carbapenemases (n = 8), the last
being either carbapenem resistant or carbapenem susceptible. OXA-23
producers are by far the most widespread carbapenemase producers
in A. baumannii (Bonnin et al., 2013a). MIC values of imipenem and
meropenem (A. baumannii is naturally resistant to ertapenem) were
determined by E-test and interpreted according to the CLSI guidelines
updated in 2014. MIC breakpoints for imipenem and meropenem
against A. baumannii were susceptibility for MICs ≤2 μg/mL, intermedi-
ate resistance 4 μg/mL, and resistance for MICs ≥8 μg/mL, as updated
in CLSI (2014). The CHROMagar Acinetobacter medium was prepared
as recommended by the manufacturer from dehydrated powder and
liquid supplement added in the form of antimicrobial selective
supplement (CR102). Bacterial suspensions of the strains with an
optical density of 0.5 McFarland (inoculum of ~5 × 107 CFU/mL) were
serially diluted in water. Ten fold dilutions were made. To quantify the
viable bacteria in each dilution, trypticase soy agar was inoculated con-
comitantly with 100 μL of suspension and incubated overnight at 37 °C;
the number of viable colonies was counted the following day. Spiked
fecal samples were made by adding 100 μL of each dilution to 900 μL
of fecal suspension that was obtained by suspending 4 g of freshly
pooled feces from four healthy volunteers in 40 mL of distilled water,
as previously described (Naas et al., 2011). A fecal suspension without
the addition of a bacterial strain was used as negative control. The low-
est detection limit of the carbapenemase producers was determined by
plating 100 μL of each dilution on CHROMagar Acinetobacter medium
(CHROMagar). Viable bacteria were counted after 24 h of culture at
37 °C. The sensitivity and speciﬁcity were determined using a cutoff
value set at ≥1 × 103 CFU/mL, as previously described (Nordmann
Table 1
Sensitivity of detection of the CHROMagar Acinetobactermedium from spiked fecal samples.
β-Lactamase content IPM MIC (μg/mL) MEM MIC (μg/mL) Lowest detection limit (CFU/mL)a
Carbapenemase Ambler class A
A. baumannii KOW GES-11 6 8 1 × 101
A. baumannii RB GES-14 32 32 1 × 101
Carbapenemase Ambler class B
A. baumannii IMP IMP-1 4 6 1 × 101
A. baumannii IMP4 IMP-4 24 16 1 × 102
Acinetobacter genomospecies 16 VIM-4 N32 N32 1 × 102
A. baumannii SIM SIM-1 N32 N32 1 × 101
A. baumannii SLO NDM-1 N32 N32 1 × 101
A. baumannii ALG NDM-1 N32 N32 1 × 101
A. baumannii EGY NDM-2 N32 N32 1 × 101
Carbapenemase Ambler class D
A. baumannii 23-B2 OXA-23 N32 N32 1 × 101
A. baumannii 23-C2 OXA-23 N32 N32 1 × 101
A. baumannii 23-D2 OXA-23 N32 N32 1 × 101
A. baumannii 23-E2 OXA-23 N32 N32 1 × 101
A. baumannii 23-F2 OXA-23 + PER-1 N32 N32 1 × 101
A. baumannii 23-G2 OXA-23 N32 N32 1 × 101
A. baumannii 23-G4 OXA-23 N32 N32 1 × 102
A. baumannii 26-C2 OXA-26 N32 N32 1 × 101
A. baumannii 40-A1 OXA-40 N32 N32 1 × 101
A. baumannii 40-A2 OXA-40 N32 N32 2 × 101
A. baumannii 40-A3 OXA-40 N32 N32 2 × 101
A. baumannii 40-A4 OXA-40 N32 N32 1 × 101
A. baumannii 40-A5 OXA-40 N32 N32 1 × 101
A. baumannii 40-D7 OXA-40 N32 N32 1 × 101
A. baumannii 40-D8 OXA-40 N32 N32 1 × 101
A. baumannii 40-D9 OXA-40 N32 N32 1 × 103
A. baumannii 72-D5 OXA-72 N32 N32 1 × 101
A. baumannii 58-A2 OXA-58 N32 N32 2 × 102
A. baumannii 58-A4 OXA-58 N32 24 2 × 102
A. baumannii 58-A7 OXA-58 + PER-2 N32 12 1 × 101
A. baumannii 58-B1 OXA-58 24 32 1 × 101
A. baumannii 58-B2 OXA-58 N32 32 2 × 102
A. baumannii SWE OXA-58 N32 24 5 × 103
A. baumannii BAR OXA-58 4 1 2 × 106
A. baumannii ITA OXA-58 N32 16 6 × 102
A. baumannii GRE OXA-58 N32 N32 1 × 103
A. haemolyticus 58-A10 OXA-58 N32 8 N1 × 106
Multiple carbapenemases
A. baumannii LIB GES-11 + OXA-23 N32 N32 1 × 101
No acquired carbapenemase
A. baumannii CB3 None 1 0.25 N1 × 106
A. baumannii CB4 None 0.25 0.25 N1 × 106
A. baumannii CB6 None 0.25 0.12 N1 × 106
A. baumannii CA9 RTG-4 0.38 0.25 N1 × 106
A. baumannii CA1 GES-12 + OXA-51 + ISAba1 32 32 1 × 102
A. baumannii CA3 OXA-51 + ISAba1 3 3 1 × 102
A. baumannii CA6 SHV-5 6 8 4 × 104
A. baumannii CA7 PER-1 1.5 0.75 N1 × 106
Abbreviations: IPM = imipenem; MEM = meropenem.
Underlined CFU counts are considered as negative results (cutoff values set at ≥1 × 103 CFU/mL).











et al., 2012), i.e., a limit detection value of 1 × 103 CFU/mL or higher was
considered as lack of detection (Table 1). This valuemay correspond to a
low-level carriage of multidrug-resistant bacteria in stools.
Carbapenemase-producing A. baumannii were well detected from
spiked stools except some OXA-58 producers (Table 1). Lack of detec-
tion was noticeable for 2 OXA-58 producers with high-level resistance
to carbapenems. The sensitivity of detection of carbapenemase-
producing A. baumannii using the CHROMagar Acinetobacter medium
(86.5%) was lower than the sensitivity of detection of carbapenem-
resistant A. baumannii (91.7%), similarly to what was previously report-
ed for detection of multidrug-resistant A. baumannii in an outbreak sit-
uation in intensive care unit in 2009 in the UK (sensitivity of 91.7%)
(Gordon and Wareham, 2009). This difference may be due to a lower
limit of detection that has been set here at 103 CFU/mL. Further studies
should clinically validate this cutoff value with carbapenem-resistant A.
baumannii isolates. Sensitivity would have been 94.6% when just con-
sidering growth or no growth, as done in this British study (Gordon
and Wareham, 2009).
We identiﬁed speciﬁcity of the CHROMagarAcinetobactermediumof
75% that was lower than that previously reported by Gordon and
Wareham (2009) (89.7%). Our speciﬁcity result was lower since we in-
cluded in “non-acquired carbapenemase-producers” 2 strains of A.
baumanniiwith insertion of ISAba1 upstream of the naturally occurring
blaOXA-51 gene. This resulted in the overexpression of this oxacillinase
gene and thus decreased susceptibility to carbapenems, as previously
reported (Brown et al., 2005; Turton et al., 2006). Moran-Gilad et al.
(2014) showed that CHROMagar Acinetobactermedium had a sensitivi-
ty of 100% for detection of isolates with MICs of imipenem N32 μg/mL
and a speciﬁcity of 100% for isolates with MICs of imipenem b1 μg/mL
(Moran-Gilad et al., 2014). Our study shows that this rule is not applicable
in all cases (Table 1). Neither imipenem nor meropenem MIC could be
strictly correlated with the detection limit of the CHROMagar Acinetobacter
medium, as exempliﬁed by the following strains, A. baumannii KOW, IMP,
and CA6, which produce GES-11, IMP-1 and SHV-5, respectively. Although
these strains showed similar MICs, the carbapenemase producers were
speciﬁcally detected on the CHROMagar Acinetobactermedium (Table 1).
Noticeably, this medium showed a good speciﬁcity, since no other
bacteria from stools were detected on the CHROMagar Acinetobacter
medium. This result correlatedwith that of previous studies on previous
formulations of this medium. Wareham and Gordon (2011) showed
that the use of the KPC supplement enabled recovery of carbapenem-
resistant A. baumannii, distinguishable from carbapenem-resistant
Enterobacteriaceae by the color of the colonies, and Barsoumian et al.
(2013) showed that the CR102 supplement prevented the growth of
other bacterial species even if carbapenem resistant (Barsoumian
et al., 2013).
Overall, the studied screening medium has a good efﬁciency for de-
tection of carriers of CRAB and is likely to be most useful during out-
breaks or when CRAB is endemic. At least, based on this study
performed with spiked stools, the CHROMagar Acinetobacter medium
can detect not only Ambler class A (GES-type carbapenemase), Ambler
class B, but also class Ambler D producers (in particular the most wide-
spread OXA-23) (Mugnier et al., 2010). The CHROMagar Acinetobacter
medium is well adapted for direct inoculation of patient samples (rectal
swabs, stools, skin, and nasal samples) in any clinical settings, as recent-
ly shown by Song et al. (2013). Use of this screening medium based on
detection of carbapenem resistance is of special interest since most of
the carbapenem-resistant A. baumannii isolates express an acquired
carbapenemase (here 36 out of 37 strains) and the carbapenem
resistance trait is associated to multidrug resistance and vice versa.
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